Proteomedix is a healthcare company whose mission is to transform prostate cancer diagnosis. The company has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis and therapy management. The lead product Proclarix® is a blood based prostate cancer test panel and risk score currently available in Europe. Proteomedix is located in the Bio-Technopark of Zurich-Schlieren, Switzerland. For more information, visit www.proteomedix.com.
18.12.2023
Swiss diagnostics company Proteomedix has officially joined forces with Blue Water Biotech to create Onconetix (venturekick.ch)
18.12.2023
Proteomedix acquired by US company (startupticker.ch)
09.06.2023
Proteomedix set for growth (startupticker.ch)
28.04.2023
Proclarix on the way to a worldwide standard (startupticker.ch)
24.09.2021
Chinese cancer screening company invests in Proteomedix (startupticker.ch)
No Jobs
ProteoMediX - Enabling Personalized Medicine
ProteoMediX: Finalist zkb pionierpreis technopark 2013
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
The venture business plan competition takes place every year and combines a competition, learning events and contact form in one. It is an initiative of the ETH Zurich, CTI and McKinsey.
CTI Start-up enables entrepreneurs to realize their innovative idea professionally.
In a process of three phases, over forty experienced coaches guide start-up companies on their way to enter the market successfully and attract financing. At the end of the coaching process, the most promising start-up companies have the opportunity to receive the prestigious CTI Start-up ’Label’. In addition, the companies benefit from the wide CTI Start-up network of industry experts, experienced entrepreneurs, business angels, venture capitalists and has access to foundations such as de Vigier, STI, FIT, Gebert, Rüf, etc.
Until today, CTI Start-up reviewed more than 1 800 projects, and awarded over 200 start-up enterprises with the CTI Start-up Label. Over 85% of these companies are still in business and some have shown remarkable growth, which is a sign that CTI Start-up guides them to sustainable success.
CTI also promotes the culture of entrepreneurship at universities, teaching hospitals, technical institutes as well as universities of applied sciences. CTI Entrepreneurship offers workshops to students on how to bring innovation to the market.
http://www.vpf.ethz.ch/transfer/firmgruend/spinoff_list/by_years/2009
Website:
www.proteomedix.com
Headquarter:
Schlieren
Foundation Date:
March 2010
Technology:
Sectors: